INMB Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
INmune Bio (INMB) is not a strong buy right now for a beginner long-term investor with $50,000-$100,000 to deploy. The stock has a mildly constructive short-term technical setup, but the fundamentals remain weak, there is no recent news catalyst, and the long-term visibility is still limited. I would not buy aggressively at this moment; hold off until there is clearer operating improvement or a better confirmed entry.
INMB is trading pre-market at 1.42, just above pivot support at 1.416 and below resistance at 1.495. MACD histogram is positive and expanding, which is a short-term bullish sign. RSI_6 at 56.96 is neutral-to-slightly bullish, and moving averages are converging, suggesting a possible base-building phase rather than a strong trend. However, the provided pattern estimate points to weakness over the next week and month, which tempers the near-term setup.
Lucid Capital upgraded INMB to Buy from Neutral and raised its price target to $9 from $2, citing expanded pipeline value from CORDStrom therapy for recessive dystrophic epidermolysis bullosa. Options positioning is also bullish with a low put-call ratio. Technically, MACD is improving and price is near pivot support.
There has been no recent news in the last week, so there is no immediate event-driven catalyst. Hedge funds and insiders are both neutral, showing no meaningful accumulation trend. The business is still loss-making, with Q4 2025 net income of -$5.264M and EPS of -0.20, both worse year over year. The stock trend model also suggests negative returns over the next week and month.
In 2025/Q4, revenue was flat at 0, so there is no evidence of commercial growth yet. Net income fell to -$5.264M, down 42.89% YoY, and EPS declined 51.22% YoY to -0.20, indicating worsening profitability. Gross margin was 100, but that is not meaningful without revenue generation. For a long-term beginner investor, the latest quarter does not yet support a confident buy decision.
On 2026-03-11, Lucid Capital upgraded INMB to Buy from Neutral and increased its price target from $2 to $9, which is a strong positive shift in Wall Street sentiment. The bull case is based on broader pipeline value, especially CORDStrom. The pro view is that analysts see meaningful upside if pipeline value is realized; the con view is that this is still a highly speculative biotech with no recent operational traction and no broad confirmation from other sentiment indicators.
